CD19 and plasma cell myeloma: For example, CD19-targeting chimeric antigen receptor T cells (CAR-Ts) and the bispecific T-cell engager (BiTE) blinatumomab have efficacy against CD19-bearing tumors, such as multiple myeloma and acute lymphoblastic leukemia (28, 29).